

## Memorandum

**To:** NCIMS Appendix N Modification Committee

**From:** Dr. Mark Moorman, FDA-CFSAN

**Date:** January 2, 2020



**Subject:** 2015 Proposal 211 Pilot Program

In this memo FDA documents its support for the motion passed by the NCIMS Executive Board on October 24, 2019:

**“The NCIMS Executive Board supports the recommendation by FDA that the current drug residue testing pilot protocol of testing for individual drugs, initiated by Proposal #15-211, be discontinued by the Appendix N Modification Committee and that the Committee explore a new approach in partnership with the NCIMS and FDA – to strengthen our system to minimize the risk of drug residues in milk, including means of verification to ensure the system is being effectively implemented.”**

FDA encourages the Appendix N Modification Committee:

- To develop a comprehensive approach to minimizing the risk of drug residues in milk, considering dairy farms, processing plants, and retail.
- To identify and implement mitigation strategies to reduce the prevalence of drug residues in milk, as well as to develop a means of verification to make sure the system is being implemented and is effective, including consideration of a continuous multi-drug random surveillance program.

FDA would welcome the opportunity to collaborate with NCIMS on this approach to minimizing the risk of drug residues in milk.